Tarsons Products Q2 Results 2026: Net loss ₹0 Cr, Revenue ₹124 Cr
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹124Cr
- Net profit
- −₹0Cr
- Margin
- 25.1%
Guidance rank: #11 of 13 in Healthcare Equipment & Supplies
See the sector's top 10 — free with your mobile number.
Tarsons Products Ltd Q2 FY27 key numbers
- Revenue
- Revenue from operations for the quarter ended September 30, 2026: ₹1,002.32 million (Standalone), ₹1,236.50 million (Consolidated).
As stated in Tarsons Products Ltd's Q2 FY27 investor presentation · published 12 Nov 2026. Reported figures, not investment advice.
Based on Tarsons Products Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Revenue from operations for the quarter ended September 30, 2026: ₹1,002.32 million (Standalone), ₹1,236.50 million (Consolidated). Quarter ended September 30, 2026 (Standalone, Page 10):.
From Tarsons Products Ltd's Q2 FY27 earnings-call transcript · updated 12 Nov 2026.
How did Tarsons Products' revenue grow in the September 2026 quarter?
- Revenue from operations for the quarter ended September 30, 2026: ₹1,002.32 million (Standalone), ₹1,236.50 million (Consolidated).
- Year-on-year change in revenue (Standalone): up from ₹805.08 million in Q2 FY2025 to ₹1,002.32 million in Q2 FY2026 (~24.5% increase).
- Year-on-year change in revenue (Consolidated): up from ₹1,023.29 million in Q2 FY2025 to ₹1,236.50 million in Q2 FY2026 (~20.9% increase).
What happened to Tarsons Products' margins in Q2 FY27?
See what Tarsons Products Ltd said on profitability & margins — free account, 30 seconds.
What capex is Tarsons Products planning?
2 more points from Tarsons Products Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Equipment & Supplies
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Tarsons Products raising money or cutting debt?
See what Tarsons Products Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Tarsons Products' order book?
See what Tarsons Products Ltd said on order book & pipeline — free account, 30 seconds.
Tarsons Products Ltd — Quarterly revenue & net profit
Tarsons Products Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 |
|---|---|
| Revenue | 124 |
| Operating profit (EBITDA) | 31 |
| Operating margin | 25.1% |
| Profit before tax | 1 |
| Net profit (PAT) | -0 |
| EPS (₹) | -0.06 |
Source: Tarsons Products Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹124 Cr, net loss ₹0 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Healthcare Equipment & Supplies
- Poly Medicure Q2 FY27 results
- Molbio Diagnosti Q2 FY27 results
- Sahajanand Medi Q2 FY27 results
- Laxmi Dental Q2 FY27 results
- Vasa Denticity Q2 FY27 results
- OSEL Devices Q2 FY27 results
- Nureca Q2 FY27 results
- Vaidya Sane Q2 FY27 results
All Q2 FY27 results | Healthcare Equipment & Supplies rankings
Continue your research
What Tarsons Products's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- OSEL Devices (Q2 FY27)
31.8% increase ((19,363.37 . Key results statement takeaways from OSEL Devices Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Avience Biomedicals (Q2 FY27)
430.93 Lakhs or approximately 16.07%. Key results statement takeaways from Avience Biomedicals Ltd's Q2 FY27 results statement — and how it ranks against sector
- Vasa Denticity (Q2 FY27)
Growth levers prioritize increasing average revenue per user (ARPU) rather than just increasing order volume or average order value (AOV), which still has room…
- Vaidya Sane (Q2 FY27)
Year-on-year (YoY) change: +23% (from INR 687 Lakhs in Sep 2025) . Key results statement takeaways from Vaidya Sane Ayurved Laboratories Ltd's Q2 FY27 results s
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Equipment & Supplies
on management's own guidance
- Strong growth2
- Strong growth1
- Poly MedicureGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Tarsons Products Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Tarsons Products Ltd Q2 FY27 results?
Revenue from operations for the quarter ended September 30, 2026: ₹1,002.32 million (Standalone), ₹1,236.50 million (Consolidated). Quarter ended September 30, 2026 (Standalone, Page 10):.
What is Tarsons Products Ltd share price analysis?
Tarsons Products Ltd currently shows a neutral. The stock trades at a P/E of 139.9 with a market cap of ₹1,656 Cr. Investors should review the full earnings analysis for detailed insights.
Is Tarsons Products Ltd planning capital expenditure?
The presentation states the following on capex, capacity expansion, or new projects:.
Keep Tarsons Products Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.